OptimizeRx (OPRX) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
24 Mar, 2026Corporate profile and market position
Leading provider of technology solutions connecting life sciences, physicians, and patients to improve therapy adherence.
Operates the largest patient point-of-care network in the U.S., reaching most physicians and patients.
Employs about 130 staff across the U.S. and Croatia, with revenue per FTE exceeding $800K.
Listed on NASDAQ with a market cap of ~$111.3M, $23.4M in cash, and $25.7M in debt as of early 2026.
Technology and platform capabilities
Dynamic Audience Activation Platform (DAAP) delivers predictive, privacy-safe marketing across clinical and personal platforms.
Platform connects over 2 million healthcare professionals and 240 million patients, integrating with 300+ EHRs.
DAAP supports ~350 brands, covering 45% of the top 200 brands, with only 10% solution penetration.
DAAP deals typically range from $0.5M to $1.5M, leveraging AI for targeted marketing execution.
Market opportunity and growth drivers
U.S. pharma digital ad spend projected to reach $21.6B by 2026, with pharma accounting for nearly 90% of industry digital ad spending.
Current DAAP opportunity with existing brands estimated at $2B–$3B.
Platform addresses key pharma challenges: brand visibility, specialty medication shift, EHR overload, affordability, interoperability, and script abandonment.
Latest events from OptimizeRx
- Record FY2025 results, margin gains, and a $10M buyback amid cautious 2026 outlook.OPRX
Q4 202526 Mar 2026 - Q3 2025 saw 22% revenue growth, margin expansion, and raised guidance for 2025–2026.OPRX
Q3 20253 Feb 2026 - Q2 revenue up 36% to $18.8M, gross margin 62.2%, full-year guidance reaffirmed.OPRX
Q2 20242 Feb 2026 - Q3 revenue up 30% to $21.3M; 2024 guidance $88–92M, with strong margin and client growth.OPRX
Q3 202414 Jan 2026 - Q4 and FY 2024 revenue and margin gains set up strong 2025 guidance and subscription growth.OPRX
Q4 202426 Dec 2025 - Plans to raise up to $75M via flexible securities offerings to fund AI-driven healthcare marketing.OPRX
Registration Filing16 Dec 2025 - Proxy seeks approval for board nominees, executive pay, and auditor, highlighting governance and ESG.OPRX
Proxy Filing1 Dec 2025 - Stockholder plans to nominate two board candidates; board's recommendation pending proxy filing.OPRX
Proxy Filing1 Dec 2025 - Q1 2025 revenue up 11%, net loss narrowed, and guidance raised on strong contracted growth.OPRX
Q1 202526 Nov 2025